Published in J Am Heart Assoc on April 23, 2013
Crucial Role of miR-433 in Regulating Cardiac Fibrosis. Theranostics (2016) 1.66
Atrial fibrillation and microRNAs. Front Physiol (2014) 1.31
MicroRNAs in heart development. Curr Top Dev Biol (2012) 1.06
miR-185 plays an anti-hypertrophic role in the heart via multiple targets in the calcium-signaling pathways. PLoS One (2015) 0.94
The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv (2014) 0.94
Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice. Mol Ther (2014) 0.92
MicroRNA-1 downregulation increases connexin 43 displacement and induces ventricular tachyarrhythmias in rodent hypertrophic hearts. PLoS One (2013) 0.89
Small molecules, big effects: the role of microRNAs in regulation of cardiomyocyte death. Cell Death Dis (2014) 0.88
Fibulin-2 deficiency attenuates angiotensin II-induced cardiac hypertrophy by reducing transforming growth factor-β signalling. Clin Sci (Lond) (2014) 0.87
Circulating level of miR-378 predicts left ventricular hypertrophy in patients with aortic stenosis. PLoS One (2014) 0.84
The role of microRNAs in skin fibrosis. Arch Dermatol Res (2013) 0.83
Differential expression of microRNAs in ischemic heart disease. Drug Discov Today (2014) 0.82
The myriad essential roles of microRNAs in cardiovascular homeostasis and disease. Genes Dis (2014) 0.81
Overview of MicroRNAs in Cardiac Hypertrophy, Fibrosis, and Apoptosis. Int J Mol Sci (2016) 0.80
Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res (2016) 0.79
Cardiac Disease Status Dictates Functional mRNA Targeting Profiles of Individual MicroRNAs. Circ Cardiovasc Genet (2015) 0.78
The Role of MicroRNAs in Antiarrhythmic Therapy for Atrial Fibrillation. Arrhythm Electrophysiol Rev (2015) 0.78
MicroRNAs; easy and potent targets in optimizing therapeutic methods in reparative angiogenesis. J Cell Mol Med (2015) 0.78
Antisense MicroRNA Therapeutics in Cardiovascular Disease: Quo Vadis? Mol Ther (2015) 0.78
Exercise mediated protection of diabetic heart through modulation of microRNA mediated molecular pathways. Cardiovasc Diabetol (2017) 0.78
Adeno-associated virus-mediated gene therapy in cardiovascular disease. Curr Opin Cardiol (2015) 0.77
Novel epigenetic-based therapies useful in cardiovascular medicine. World J Cardiol (2016) 0.77
Noncoding RNA as regulators of cardiac fibrosis: current insight and the road ahead. Pflugers Arch (2016) 0.76
Fibulin-2 is essential for angiotensin II-induced myocardial fibrosis mediated by transforming growth factor (TGF)-β. Lab Invest (2016) 0.75
MicroRNA and hyperglycemic memory in the diabetic heart. J Thorac Dis (2016) 0.75
MicroRNAs: pleiotropic players in congenital heart disease and regeneration. J Thorac Dis (2017) 0.75
Diagnostic and prognostic value of circulating microRNAs in heart failure with preserved and reduced ejection fraction. World J Cardiol (2015) 0.75
Over-expression of microRNA-1 causes arrhythmia by disturbing intracellular trafficking system. Sci Rep (2017) 0.75
The Role and Molecular Mechanism of Non-Coding RNAs in Pathological Cardiac Remodeling. Int J Mol Sci (2017) 0.75
Chronic Losartan Treatment Up-Regulates AT1R and Increases the Heart Vulnerability to Acute Onset of Ischemia and Reperfusion Injury in Male Rats. PLoS One (2015) 0.75
MicroRNA-19b is a potential biomarker of increased myocardial collagen cross-linking in patients with aortic stenosis and heart failure. Sci Rep (2017) 0.75
Translational Perspective on Epigenetics in Cardiovascular Disease. J Am Coll Cardiol (2017) 0.75
Sexual dimorphisms of mRNA and miRNA in human/murine heart disease. PLoS One (2017) 0.75
MicroRNAs Association in the Cardiac Hypertrophy Secondary to Complex Congenital Heart Disease in Children. Pediatr Cardiol (2017) 0.75
Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases. Heart Fail Rev (2017) 0.75
Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension. J Transl Med (2017) 0.75
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
The impact of microRNAs on protein output. Nature (2008) 32.39
Widespread changes in protein synthesis induced by microRNAs. Nature (2008) 31.44
Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature (2010) 22.04
Cardiac excitation-contraction coupling. Nature (2002) 18.48
Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet (2002) 17.20
The microRNA.org resource: targets and expression. Nucleic Acids Res (2007) 16.26
The diverse functions of microRNAs in animal development and disease. Dev Cell (2006) 15.62
Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet (2004) 12.97
Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell (2007) 12.72
MicroRNA-133 controls cardiac hypertrophy. Nat Med (2007) 11.68
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature (2008) 10.73
Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol (2006) 10.71
A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A (2006) 10.09
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A (2008) 9.86
MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation (2007) 6.41
Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med (1991) 6.08
MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res (2007) 5.65
Altered microRNA expression in human heart disease. Physiol Genomics (2007) 5.64
Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness. Circ Res (2001) 5.08
MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest (2007) 4.76
MicroRNAs are aberrantly expressed in hypertrophic heart: do they play a role in cardiac hypertrophy? Am J Pathol (2007) 4.65
Measurement of cardiac function using pressure-volume conductance catheter technique in mice and rats. Nat Protoc (2008) 4.50
Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol (2001) 4.17
Signaling pathways for cardiac hypertrophy and failure. N Engl J Med (1999) 3.97
miR-133 and miR-30 regulate connective tissue growth factor: implications for a role of microRNAs in myocardial matrix remodeling. Circ Res (2008) 3.96
The cellular and molecular response of cardiac myocytes to mechanical stress. Annu Rev Physiol (1997) 3.70
Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res (2006) 3.63
Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res (2008) 3.18
Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium. Circ Res (1994) 2.82
Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation (1999) 2.45
Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther (2008) 2.27
MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol (2009) 2.18
Gene expression of the cardiac Na(+)-Ca2+ exchanger in end-stage human heart failure. Circ Res (1994) 2.04
Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res (1988) 2.02
The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res (2008) 1.94
Altered sarcoplasmic reticulum Ca2(+)-ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest (1990) 1.94
Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation (2009) 1.92
Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res (2010) 1.90
Alterations in sarcoplasmic reticulum gene expression in human heart failure. A possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res (1993) 1.83
Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat Rev Drug Discov (2007) 1.83
Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation (1999) 1.75
Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation (2009) 1.71
Novel technique of aortic banding followed by gene transfer during hypertrophy and heart failure. Physiol Genomics (2002) 1.27
Dynamic correction for parallel conductance, GP, and gain factor, alpha, in invasive murine left ventricular volume measurements. J Appl Physiol (1985) (2009) 1.24
Extracellular matrix protein fibulin-2 is expressed in the embryonic endocardial cushion tissue and is a prominent component of valves in adult heart. Dev Biol (1995) 1.23
The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med (2008) 1.21
Na+-Ca2+ exchange and sarcoplasmic reticular Ca2+ regulation in ventricular myocytes from transgenic mice overexpressing the Na+-Ca2+ exchanger. J Physiol (1998) 1.19
Fibulin-2 expression marks transformed mesenchymal cells in developing cardiac valves, aortic arch vessels, and coronary vessels. Dev Dyn (2001) 1.17
Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J Cell Sci (2010) 1.14
Measurements of Ca2+ entry and sarcoplasmic reticulum Ca2+ content during the cardiac cycle in guinea pig and rat ventricular myocytes. Biophys J (1997) 1.10
Differential regulation of fibulin, tenascin-C, and nidogen expression during wound healing of normal and glucocorticoid-treated mice. Exp Cell Res (1996) 1.10
Fibulin-2 is present in murine vascular lesions and is important for smooth muscle cell migration. Cardiovasc Res (2006) 1.09
Connective tissue content and myocardial stiffness in pressure overload hypertrophy. A combined study of morphologic, morphometric, biochemical, and mechanical parameters. Basic Res Cardiol (1983) 1.07
SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. Eur Heart J (2012) 1.05
Functional interplay between dual site phospholambam phosphorylation: insights from genetically altered mouse models. Basic Res Cardiol (2002) 0.91
Loss of fibulin-2 protects against progressive ventricular dysfunction after myocardial infarction. J Mol Cell Cardiol (2011) 0.86
Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med (2007) 3.98
Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med (2012) 3.53
Meta-analysis of traditional Chinese patent medicine for ischemic stroke. Stroke (2007) 3.46
Functional near-infrared fluorescence imaging for cardiac surgery and targeted gene therapy. Mol Imaging (2002) 3.37
Titin isoform switch in ischemic human heart disease. Circulation (2002) 3.05
Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail (2009) 2.89
Enhancement of cardiac function and suppression of heart failure progression by inhibition of protein phosphatase 1. Circ Res (2005) 2.52
Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J Am Coll Cardiol (2008) 2.29
Role of health insurance in averting economic hardship in families after acute stroke in China. Stroke (2009) 2.13
Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality. Circ Res (2013) 2.12
In vivo tracking of stem cells for clinical trials in cardiovascular disease. Circulation (2004) 2.11
Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res (2012) 2.06
Effects of Na(+)/Ca(2+)-exchanger overexpression on excitation-contraction coupling in adult rabbit ventricular myocytes. J Mol Cell Cardiol (2002) 2.00
Functional consequences of caspase activation in cardiac myocytes. Proc Natl Acad Sci U S A (2002) 1.98
Type 1 phosphatase, a negative regulator of cardiac function. Mol Cell Biol (2002) 1.97
Critical role for stromal interaction molecule 1 in cardiac hypertrophy. Circulation (2011) 1.91
SUMO1-dependent modulation of SERCA2a in heart failure. Nature (2011) 1.89
PICOT inhibits cardiac hypertrophy and enhances ventricular function and cardiomyocyte contractility. Circ Res (2006) 1.80
Systems pharmacology of adverse event mitigation by drug combinations. Sci Transl Med (2013) 1.78
Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling. Proc Natl Acad Sci U S A (2004) 1.77
Angiotensin II-induced negative inotropy in rat ventricular myocytes: role of reactive oxygen species and p38 MAPK. Am J Physiol Heart Circ Physiol (2005) 1.73
Targeted sarcoplasmic reticulum Ca2+ ATPase 2a gene delivery to restore electrical stability in the failing heart. Circulation (2012) 1.71
Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer. Mol Ther (2006) 1.71
Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation (2009) 1.71
Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J Am Coll Cardiol (2008) 1.70
Stem cell factor gene transfer promotes cardiac repair after myocardial infarction via in situ recruitment and expansion of c-kit+ cells. Circ Res (2012) 1.68
Cardiac sodium channel gene variants and sudden cardiac death in women. Circulation (2007) 1.67
PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling. Circ Res (2008) 1.66
CaMKII inhibition protects against necrosis and apoptosis in irreversible ischemia-reperfusion injury. Cardiovasc Res (2006) 1.64
Increased leakage of sarcoplasmic reticulum Ca2+ contributes to abnormal myocyte Ca2+ handling and shortening in sepsis. Crit Care Med (2005) 1.63
SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure. Sci Transl Med (2013) 1.59
Targeting phospholamban by gene transfer in human heart failure. Circulation (2002) 1.55
Cyclosporine attenuates cardiomyocyte hypertrophy induced by RAF1 mutants in Noonan and LEOPARD syndromes. J Mol Cell Cardiol (2011) 1.55
Inhibition of PKCα/β with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury. Circ Res (2011) 1.55
Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins. J Mol Cell Cardiol (2007) 1.54
Inducible expression of active protein phosphatase-1 inhibitor-1 enhances basal cardiac function and protects against ischemia/reperfusion injury. Circ Res (2009) 1.52
Closure versus medical therapy for preventing recurrent stroke in patients with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack. Cochrane Database Syst Rev (2015) 1.47
Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol (2004) 1.46
Gene therapy for heart failure. Circ Res (2012) 1.46
Targeted SERCA2a gene expression identifies molecular mechanism and therapeutic target for arrhythmogenic cardiac alternans. Circ Arrhythm Electrophysiol (2009) 1.44
Role of protein phosphatase-1 inhibitor-1 in cardiac physiology and pathophysiology. J Mol Cell Cardiol (2009) 1.42
Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. J Clin Invest (2011) 1.42
AKT signalling in the failing heart. Eur J Heart Fail (2011) 1.41
Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther (2010) 1.41
SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure. Circ Arrhythm Electrophysiol (2011) 1.40
Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol (2008) 1.35
A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem Biol (2011) 1.35
Distinct roles of microRNA-1 and -499 in ventricular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes. PLoS One (2011) 1.34
Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther (2011) 1.34
Sarco/endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ Res (2005) 1.33
CXCR4 modulates contractility in adult cardiac myocytes. J Mol Cell Cardiol (2006) 1.31
Prevention of ventricular arrhythmias with sarcoplasmic reticulum Ca2+ ATPase pump overexpression in a porcine model of ischemia reperfusion. Circulation (2008) 1.30
Localization and quantification of platelet-rich thrombi in large blood vessels with near-infrared fluorescence imaging. Circulation (2006) 1.28
The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis. J Mol Cell Cardiol (2010) 1.27
Novel technique of aortic banding followed by gene transfer during hypertrophy and heart failure. Physiol Genomics (2002) 1.27
Plasticity of surface structures and β(2)-adrenergic receptor localization in failing ventricular cardiomyocytes during recovery from heart failure. Circ Heart Fail (2012) 1.23
The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med (2008) 1.21
Early repair of moderate ischemic mitral regurgitation reverses left ventricular remodeling: a functional and molecular study. Circulation (2007) 1.20
Time-calibrated Milankovitch cycles for the late Permian. Nat Commun (2013) 1.20
SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol Ther (2010) 1.18
A novel mutant cardiac troponin C disrupts molecular motions critical for calcium binding affinity and cardiomyocyte contractility. Biophys J (2008) 1.18
Toll-like receptor 2 activation by bacterial peptidoglycan-associated lipoprotein activates cardiomyocyte inflammation and contractile dysfunction. Crit Care Med (2007) 1.16
Ca2+ cycling and new therapeutic approaches for heart failure. Circulation (2010) 1.16
Association between metabolic syndrome and risk of stroke: a meta-analysis of cohort studies. Cerebrovasc Dis (2008) 1.16
Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEB J (2013) 1.15
Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy. Nat Rev Cardiol (2012) 1.15
Shrink-film configurable multiscale wrinkles for functional alignment of human embryonic stem cells and their cardiac derivatives. Adv Mater (2011) 1.14
Abnormal muscle mechanosignaling triggers cardiomyopathy in mice with Marfan syndrome. J Clin Invest (2014) 1.13
Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes. Stem Cells Transl Med (2013) 1.13
Targeting calcium cycling proteins in heart failure through gene transfer. J Physiol (2003) 1.12
Quantitation of CXCR4 expression in myocardial infarction using 99mTc-labeled SDF-1alpha. J Nucl Med (2008) 1.12
Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy. Nat Clin Pract Cardiovasc Med (2008) 1.12
Rescuing the failing heart by targeted gene transfer. J Am Coll Cardiol (2011) 1.11
In vivo cardiac gene transfer of Kv4.3 abrogates the hypertrophic response in rats after aortic stenosis. Circulation (2004) 1.11
Effects of CXCR4 gene transfer on cardiac function after ischemia-reperfusion injury. Am J Pathol (2010) 1.10
Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model. Am J Physiol Heart Circ Physiol (2006) 1.09
Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells. Cell Reprogram (2010) 1.08
β2-Adrenergic receptor signaling in the cardiac myocyte is modulated by interactions with CXCR4. J Cardiovasc Pharmacol (2010) 1.08
Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol (2006) 1.06
SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. Eur Heart J (2012) 1.05
Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways. J Biol Chem (2011) 1.05